Covalently closed-circular hepatitis B virus DNA reduction with entecavir or lamivudine

Table 4 Significant associations of baseline and on-treatment factors with hepatic hepatitis B virus cccDNA change from baseline at week 48 in univariate linear regression analysis (adjusted for treatment)

		Estimate1	95%CI	P value
Baseline	Serum HBV DNA, per 1 log10 IU/mL	-0.05	-0.08, -0.01	0.0106
	ALT ≥ 2.6 × ULN : < 2.6 × ULN	-0.42	-0.56, -0.28	< 0.0001
On-treatment	Serum HBV DNA, per 1 log10 IU/mL change from baseline at week 48	0.11	0.08, 0.14	< 0.0001
	Total hepatic HBV DNA, per 1 log10 IU/mL change from baseline at week 48	0.35	0.28, 0.42	< 0.0001
	Knodell necroinflammatory score, per 1 unit change from baseline at week 48	0.04	0.01, 0.06	0.0062
	ALT, per 1 U/L change from baseline at week 48	1.51 × 10-3	0.98 × 10-3, 2.05 × 10-3	< 0.0001
	No HBeAg loss at week 48 : HBeAg loss at week 48	-0.20	-0.38, -0.02	0.0338

¹log₁₀ copies/HGEq. ULN: Upper limit of normal; HBV: Hepatitis B virus; HBeAg: Hepatitis B e antigen; ALT: Alanine aminotransferase.